Envíe este artículo por correo electrónico 
Cáncer de pulmón. Últimas tendencias en su diagnóstico, tratamiento basado en cribado genético-molecular desde la expectativa de la medicina de precisión
Resumen
El cáncer de pulmón como enfermedad neoplásica maligna sigue siendo hoy día un importante problema de salud pública, debido al tabaquismo como el principal factor de riesgo, ya que este se comporta como una enfermedad adictiva, crónica y recidivante. En el presente artículo se hace un revisión en las últimas tendencias en su diagnóstico, tratamiento basado en los cambios más relevantes y la importancia de los hallazgos genéticos moleculares para un mejor enfoque clínico y terapéutico desde la expectativa de la medicina de precisión. Se realizó una revisión de la literatura centrada en estudios publicados entre 2010 y 2024 en la base de datos PubMed Central para recopilar las últimas investigaciones sobre el cáncer de pulmón. Publicaciones originales, incluyendo ensayos clínicos, revisiones bibliográficas y artículos de revisión. Se seleccionaron estudios en función de su relevancia para el cáncer de pulmón; estudios que encontraron/teorizaron nuevos descubrimientos o se basaron en evidencia anterior con nuevos ensayos/investigaciones. Por lo que se puede concluir que estos descubrimientos contribuyan significativamente a mejorar el pronóstico de los pacientes con esta enfermedad de mal pronóstico.
Recibido: 19 de Enero de 2026.
Aceptado: 1 de Mayo de 2026.
Publicación online: 28 de Septiembre de 2026.
Palabras clave
Texto completo:
PDFReferencias
Mercer, R. Estadísticas canadienses sobre el cáncer: Informe especial de 2020 sobre el cáncer de pulmón; Centro Canadiense de Investigación Aplicada para el Control del Cáncer: Vancouver, BC, Canadá, 2020.
Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021; 25: 45-52. [PubMed]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424. [PubMed] [Google Schoolar]
Keith RL. Cáncer de pulmón [Internet]. 2023 [citado 24 de octubre de 2024]. [Google Schoolar]
Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L. [citado 5 de mayo de 2024]. Global Cancer Observatory: Cancer Today. 2024. [Google Schoolar]
Travis, WD: Actualización sobre el carcinoma de células pequeñas y su diferenciación del carcinoma de células escamosas y otros carcinomas de células no pequeñas. Mod. Pathol. 2012 , 25, S18–S30.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71: 209-49. [PubMed]
Barrionuevo Cornejo Carlos, Dueñas Hancco Daniela. Clasificación actual del carcinoma de pulmón. Consideraciones histológicas, inmunofenotípicas, moleculares y clínicas. Horiz. Med. [Internet]. 2019;19: 74-83.
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017; 67: 93-9. [PubMed] [Google Schoolar]
Sun Q, Zheng S, Tang W, Wang X, Wang Q, Zhang R, Zhang N, Ping W. Prediction of lung adenocarcinoma prognosis and diagnosis with a novel model anchored in circadian clock-related genes. Sci Rep. 2024. 14: 18202 [PubMed] [Google Schoolar]
Casallas Gómez A. Inmunohistoquímica y arquitectura genómica en el cáncer pulmonar: perspectiva desde la cirugía de tórax. Revista Colombiana de Neumología 2021; 33: 5-18. [Google Schoolar]
Zhang Y, Vaccarella S, Morgan E, Li M, Etxeberria J, Chokunonga E, Manraj SS, Kamate B, Omonisi A, Bray F. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023; 24: 1206-18. [PubMed] [Google Schoolar]
Wood DE, Kazerooni EA, Baum SL, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Lennes IT, Leung ANC, Makani SS, Massion PP, Mazzone P, Merritt RE, Meyers BF, Midthun DE, Pipavath S, Pratt C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Schiebler ML, Tong BC, Travis WD, Wei B, Yang SC, Gregory KM, Hughes M. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018; 16: 412-41. [PubMed] [Google Schoolar]
De Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K., Heuvelmans MA, Lammers JJ, Weenink C., Yousaf-Khan U., Horeweg N. Reducción de la mortalidad por cáncer de pulmón con detección por tomografía computarizada de volumen en un ensayo aleatorizado. N. inglés. J Med. 2020; 382: 503–13.
Ye J, Liu H, Xu ZL, Zheng L, Liu RY. Identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma. J Clin Lab Anal. 2019; 33: e22990. [PubMed] [Google Schoolar]
National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395–409. [PubMed] [Google Schoolar]
Cotton LB, Bach PB, Cisar C, Schonewolf CA, Tennefoss D, Vachani A, Carter-Bawa L, Zaidi AH. Innovations in Early Lung Cancer Detection: Tracing Evolution and Advancements in Screening. J Clin Med. 2024; 13: 4911. [PubMed] [Google Schoolar]
Amos CI, Dennis J, Wang Z, Byun J, Schumacher FR, Gayther SA, Casey G, Hunter DJ, Sellers TA, Gruber SB, Dunning AM, Michailidou K, Fachal L, Doheny K, Spurdle AB, Li Y, Xiao X, Romm J, Pugh E, Coetzee GA, Hazelett DJ, Bojesen SE, Caga-Anan C, Haiman CA, Kamal A, Luccarini C, Tessier D, Vincent D, Bacot F, Van Den Berg DJ, Nelson S, Demetriades S, Goldgar DE, Couch FJ, Forman JL, Giles GG, Conti DV, Bickeböller H, Risch A, Waldenberger M, Brüske-Hohlfeld I, Hicks BD, Ling H, McGuffog L, Lee A, Kuchenbaecker K, Soucy P, Manz J, Cunningham JM, Butterbach K, Kote-Jarai Z, Kraft P, FitzGerald L, Lindström S, Adams M, McKay JD, Phelan CM, Benlloch S, Kelemen LE, Brennan P, Riggan M, O'Mara TA, Shen H, Shi Y, Thompson DJ, Goodman MT, Nielsen SF, Berchuck A, Laboissiere S, Schmit SL, Shelford T, Edlund CK, Taylor JA, Field JK, Park SK, Offit K, Thomassen M, Schmutzler R, Ottini L, Hung RJ, Marchini J, Amin Al Olama A, Peters U, Eeles RA, Seldin MF, Gillanders E, Seminara D, Antoniou AC, Pharoah PD, Chenevix-Trench G, Chanock SJ, Simard J, Easton DF. The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiol Biomarkers Prev. 2017; 26: 126-35. [PubMed] [Google Schoolar]
Ohno Y, Koyama H, Nogami M, Takenaka D, Matsumoto S, Yoshimura M, Kotani Y, Sugimura K. Postoperative lung function in lung cancer patients: comparative analysis of predictive capability of MRI, CT, and SPECT. AJR Am J Roentgenol. 2007; 189: 400-8. [PubMed] [Google Schoolar]
Sommer G, Tremper J, Koenigkam-Santos M, Delorme S, Becker N, Biederer J, Kauczor HU, Heussel CP, Schlemmer HP, Puderbach M. Lung nodule detection in a high-risk population: comparison of magnetic resonance imaging and lowdose computed tomography. Eur J Radiol. 2014; 83: 600-5. [PubMed] [Google Schoolar]
Khan KA, Nardelli P, Jaeger A, O'Shea C, Cantillon-Murphy P, Kennedy MP. Navigational Bronchoscopy for Early Lung Cancer: A Road to Therapy. Adv Ther. 2016; 33: 580-96. [PubMed] [Google Schoolar]
Sehgal IS, Agarwal R, Dhooria S, Prasad KT, Aggarwal AN. Role of EBUS TBNA in Staging of Lung Cancer: A Clinician's Perspective. J Cytol. 2019; 36: 61-4. [PubMed] [Google Schoolar]
Kokkonouzis I, Strimpakos AS, Lampaditis I, Tsimpoukis S, Syrigos KN. The role of endobronchial ultrasound in lung cancer diagnosis and staging: a comprehensive review. Clin Lung Cancer. 2012; 13: 408-15. [PubMed] [Google Schoolar]
Feldman R, Kim ES. Biomarcadores pronósticos y predictivos tras terapia con intención curativa. Ann Transl Med. 2017; 5: 374. [PubMed] [Google Schoolar]
Seijo LM, Peled N, Ajona D, Boeri M, Field JK, Sozzi G, Pio R, Zulueta JJ, Spira A, Massion PP, Mazzone PJ, Montuenga LM. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. J Thorac Oncol. 2019; 14: 343-57. [PubMed] [Google Schoolar]
Carnio S, Novello S, Papotti M, Loiacono M, Scagliotti GV. Prognostic and predictive biomarkers in early stage nonsmall cell lung cancer: tumor based approaches including gene signatures. Transl Lung Cancer Res. 2013;2: 372-81. [PubMed] [Google Schoolar]
Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, Chapman CJ, Allen J, Wood WC, Sewell HF, Robertson JF. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila). 2011;4: 1126-34. [PubMed] [Google Schoolar]
Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, Allen J, Thorpe AJ, Hamilton-Fairley G, Parsy-Kowalska CB, MacDonald IK, Jewell W, Maddison P, Robertson JF. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 2012; 33: 1319-26. [PubMed] [Google Schoolar]
Ajona D, Okrój M, Pajares MJ, Agorreta J, Lozano MD, Zulueta JJ, Verri C, Roz L, Sozzi G, Pastorino U, Massion PP, Montuenga LM, Blom AM, Pio R. Complement C4d-specific antibodies for he diagnosis of lung cancer. Oncotarget. 2017;9: 6346-55. [PubMed] [Google Schoolar]
Wadowska K, Bil-Lula I, Trembecki L, Sliwinska-Mosson M. Genetic Markers in Lung Cancer Diagnosis: A Review. Int J Mol Sci. 2020; 21: 4569. [PubMed] [Google Schoolar]
Lobera ES, Varela MA, Jimenez RL, Moreno RB. miRNA as biomarker in lung cancer. MiARN como biomarcador en cáncer de pulmón. Mol Biol Rep ; 50: 9521–7. [PubMed]
Duffy MJ. Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction. Tumour Biol. 2024; 46: S283-95. [PubMed] [Google Schoolar]
Behel V, Chougule A, Noronha V, Patil VM, Menon N, Singh A, Chopade S, Kumar R, Shah S, More S, Banavali SD, Chandrani P, Prabhash K. Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC. Clin Lung Cancer. 2022;23: 410-18. [PubMed] [Google Schoolar]
Hoang PH, Landi MT. DNA Methylation in Lung Cancer: Mechanisms and Associations with Histological Subtypes, Molecular Alterations, and Major Epidemiological Factors. Cancers (Basel). 2022; 14: 961. [PubMed] [Google Schoolar]
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: 209-49. [PubMed] [Google Schoolar]
Zamay TN, Zamay GS, Kolovskaya OS, Zukov RA, Petrova MM, Gargaun A, Berezovski MV, Kichkailo AS. Current and Prospective Protein Biomarkers of Lung Cancer. Cancers (Basel). 2017; 9: 155. [PubMed] [Google Schoolar]
Voronkova MA, Johnson B, Gandhi N, Koomen JM, Patrick M, Shanthi Bhupathi S, Wu VM, Elliott A, Vanderwalde A, Halmos B, Hazlehurst LA.. ERO1A levels are a prognostic indicator in EGFR mutated non small cell lung cancer. NPJ Precis Oncol. 2024; 8: 250. [PubMed] [Google Schoolar]
Chen R, Manochakian R, James L, Azzouqa AG, Shi H, Zhang Y, Zhao Y, Zhou K, Lou Y. Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 2020; 13: 58. [PubMed] [Google Schoolar]
Altorki NK, Bhinder B, Borczuk AC, Elemento O, Mittal V, McGraw TE. A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage nonsmall cell lung cancer. Cell Rep Med. 2024; 5: 101438. [PubMed] [Google Schoolar]
Wurster S, Keller C, Imhoff D, Rades D, Dunst J, Rödel C, Hildebrandt G, Blanck O. Breathing-motion-compensated robotic guided stereotactic body radiation therapy : Patterns of failure analysis. Strahlenther Onkol. 2018; 194:143-55. [PubMed] [Google Schoolar]
Abreu CE, Ferreira PP, de Moraes FY, Neves WF Jr, Gadia R, Carvalho Hde A. Stereotactic body radiotherapy in lung cancer: an update. J Bras Pneumol. 2015; 41: 376-87. [PubMed] [Google Schoolar]
Vlaskou Badra E, Baumgartl M, Fabiano S, Jongen A, Guckenberger M. Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research. Transl Lung Cancer Res. 2021; 10: 1930-49. [PubMed] [Google Schoolar]
Shibamoto Y, Miyakawa A, Otsuka S, Iwata H. Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules? J Radiat Res, 2016: i76-i82. [PubMed] [Google Schoolar]
La'ah AS, Chiou SH. Cutting-Edge Therapies for Lung Cancer. Cells. 2024; 13: 436. [PubMed] [Google Schoolar]
Medlej ZAA, Medlej W, Slaba S, Torrecillas P, Cueto A, Urbaneja A, Garrido AJ, Lugnani F. Cryoablation and Immunotherapy: An Enthralling Synergy for Cancer Treatment. Curr Oncol. 2023; 30: 4844-60. [PubMed] [Google Schoolar]
Ma QL, Shen MO, Han N, Xu HZ, Peng XC, Li QR, Yu TT, Li LG, Xu X, Liu B, Chen X, Wang MF, Li TF. Chlorin e6 mediated photodynamic therapy triggers resistance through ATM-related DNA damage response in lung cancer cells. Photodiagnosis Photodyn Ther. 2022; 37: 102645. [PubMed] [Google Schoolar]
Sonokawa T, Obi N, Usuda J, Sudo Y, Hamakubo T. Development of a new minimally invasive phototherapy for lung cancer using antibody-toxin conjugate. Thorac Cancer. 2023;14: 645-53. [PubMed] [Google Schoolar]
Dunne M, Regenold M, Allen C. Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy. Adv Drug Deliv Rev. 2020;163-164: 98-124. [PubMed] [Google Schoolar]
Wang, M., Herbst, RS y Boshoff, C. Hacia enfoques terapéuticos personalizados para el cáncer de pulmón de células no pequeñas. Nat Med 2021; 27: 1345–56 (). [Google Schoolar]
Zhang LN, Xin T, Chen M, Gao P. Chemoresistance in mesenchymal lung cancer cells is correlated to high regulatory T cell presence in the tumor microenvironment. IUBMB Life. 2019; 71: 986-991. [PubMed] [Google Schoolar]
Bao R, Chan P. Novel compounds in the treatment of lung cancer: current and developing therapeutic agents. J Exp Pharmacol. 2011; 3: 21-34. [PubMed] [Google Schoolar]
Nooreldeen R, Bach H. Current and Future Development in Lung Cancer Diagnosis. Int J Mol Sci. 2021; 22: 8661. [PubMed] [Google Schoolar]
Sun L, Zhao Q, Miao L. Combination therapy with oncolytic viruses for lung cancer treatment. Front Oncol. 2025; 15:1524079. [PubMed] [Google Schoolar]
Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, Jänne PA, Peters S, Hirsch FR. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024;404: 803-22. [PubMed] [Google Schoolar]
Somasundaram A, Burns TF. The next generation of immunotherapy: keeping lung cancer in check. J Hematol Oncol. 2017; 10: 87. [PubMed] [Google Schoolar]
Hayashi H, Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol. 2020; 25: 818-30. [PubMed] [Google Schoolar]
Bylicki O, Barazzutti H, Paleiron N, Margery J, Assié JB, Chouaïd C. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors. BioDrugs. 2019; 33: 159-71. [PubMed] [Google Schoolar]
Zhang Y, Zhou H, Zhang L. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: antiPD-1 or anti-PD-L1? J Immunother Cancer. 2018; 6: 135. [PubMed] [Google Schoolar]
Li Y, Yan B, He S. Advances and challenges in the treatment of lung cancer. Biomed Pharmacother. 2023; 169:115891. . [PubMed] [Google Schoolar]
Liu X, Zhang Y, Zhang X, He G, Cai W. [Progress of IL-21 and Tfh Mediated Immunotherapy in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2024; 27: 550-8. [PubMed] [Google Schoolar]
Leonetti A, Wever B, Mazzaschi G, Assaraf YG, Rolfo C, Quaini F, Tiseo M, Giovannetti E. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist Updat. 2019; 46: 100644. [PubMed] [Google Schoolar]
Ramlogan-Steel CA, Steel JC, Morris JC. Lung cancer vaccines: current status and future prospects. Transl Lung Cancer Res. 2014;3: 46-52. [PubMed] [Google Schoolar]
Eager R, Nemunaitis J. GM-CSF genetransduced tumor vaccines. Mol Ther. 2005; 12: 18-27. [PubMed] [Google Schoolar]
Bidzinska J, Szurowska E. See Lung Cancer with an AI. Cancers (Basel). 2023 Feb 19;15:1321. [PubMed]
Schreuder A, Scholten ET, van Ginneken B, Jacobs C. Artificial intelligence for detection and characterization of pulmonary nodules in lung cancer CT screening: ready for practice? Transl Lung Cancer Res. 2021;10: 2378-88. [PubMed] [Google Schoolar]
Grenier PA, Brun AL, Mellot F. The Potential Role of Artificial Intelligence in Lung Cancer Screening Using LowDose Computed Tomography. Diagnostics (Basel). 2022;12: 2435. [PubMed] [Google Schoolar]
Cellina M, Cè M, Irmici G, Ascenti V, Khenkina N, Toto-Brocchi M, Martinenghi C, Papa S, Carrafiello G. Artificial Intelligence in Lung Cancer Imaging: Unfolding the Future. Diagnostics (Basel). 2022; 12: 2644. [PubMed] [Google Schoolar]
Quanyang W, Yao H, Sicong W, Linlin Q, Zewei Z, Donghui H, Hongjia L, Shijun Z. Artificial intelligence in lung cancer screening: Detection, classification, prediction, and prognosis. Cancer Med. 2024;13: e7140. [PubMed] [Google Schoolar]
de Margerie-Mellon C, Chassagnon G. Artificial intelligence: A critical review of applications for lung nodule and lung cancer. Diagn Interv Imaging. 2023; 104: 11-17. [PubMed] [Google Schoolar]
Depósito Legal: ppi201102ME3935 - ISSN: 2477-9369.
Copyright ©2012 ULA Todos los derechos reservados
 |
Todos los documentos publicados en esta revista se distribuyen bajo una
Licencia Creative Commons Atribución -No Comercial- Compartir Igual 4.0 Internacional.
Por lo que el envío, procesamiento y publicación de artículos en la revista es totalmente gratuito.